I don’t think there is any relation at all. Most

I don’t think there is any relation at all. Most people would be shocked by what is actually involved in study start-up and I am not too surprised by some delay. Every study site has to go through IRB, budgeting, training of providers and nurses involved in the study and they are also involved in the process of patient population identification and consent. Study drug has to be provisioned and available…sometimes that is routed to a special investigational pharmacy who is then responsible for drug provision. Things should pick up with the multiple trial sites now on line and many of those steps in the rear view mirror. While there needs to be a lot of inclusion exclusion criteria applied to get to patient consent, if the principal investigator is fully on board they will find the patient’s, who in turn will find far more reasons to enroll than decline and I suspect we should see fairly quick enrollment. I did a pretty deep look at inclusion/exclusion criteria and the study is well thought out and should filter out a lot of patients who if they were included could act otherwise in an overweight fashion to influence the results. Leronlimab is being given a fair shot in this trial, needs to prove its mettle but I think that is going to happen!